학술논문
A multicenter phase I–II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer
Document Type
Article
Author
Source
In The Breast December 2013 22(6):1171-1177
Subject
Language
ISSN
0960-9776